Li W.,The First Peoples Hospital of Tianmen City |
Liu K.-J.,The First Peoples Hospital of Tianmen City |
Song J.-S.,The First Peoples Hospital of Tianmen City |
Song R.,The First Peoples Hospital of Tianmen City |
Liu Z.-L.,The First Peoples Hospital of Tianmen City
International Journal of Clinical and Experimental Medicine | Year: 2015
Background: RAD51 interacting with BRCA1 and BRCA2 could modulate the penetrance of BRCA1/BRCA2 mutations, which may increase susceptibility for breast cancer by inhibiting DNA repair and genome stability. The purpose of this study was to provide refined statistical evidence for the association between RAD51 polymorphism and breast cancer risk. Design and results: We conducted a meta-analysis of 15 publications with a total of 11,766 cancer cases and 11,227 controls. We summarized the data on the association of RAD51 polymorphism with breast cancer risk and performed subgroup analyses by ethnicity and control source. The pooled ORs based on fixed-effects model did not indicate a modified risk of breast cancer associated with RAD51 polymorphism in the overall population. Nor did we find a significant association in any stratified analysis. Conclusions: This meta-analysis suggested that RAD51 polymorphism did not appear to represent a significant risk factor for breast cancer. © 2015, E-Century Publishing Corporation. All Rights Reserved.